Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Volume dropping fast. It will be shorted to red now
They got clearance on Friday.
You must be part of management. Got any Golden Plates for me?
Well, I'm no fan of Mike Houston or the rest of management for that matter.
They're idiots with a good product and an extremely undervalued stock on their hands due to their mismanagement.
But they will pr it this news- they have no choice...unless they want to be in trouble with the SEC.
Folks who think they won't somehow pr this are wrong.
Amedica must pr the FDA clearance by SEC regulations. It's a material change.
With pending China deal, I think P/S ratio of 3 is conservative.
Given the size of orders they're looking at, P/S of 3 is low:
"With more than 50,000 minimum unit sales to occur within the first two years following CFDA clearance, this agreement far surpasses total silicon nitride unit sales to-date, and marks a momentous time for Amedica,"
From April press release: http://www.amedica.com/news-media/press-releases/detail/74/amedica-signs-exclusive-chinese-silicon-nitride
So big question now is, with FDA approval in the bag, does CFDA come soon?
Market cap $25M and has $20M in sales before this FDA approval.
It will run much higher tomorrow imo. Was a $7 stock a year ago, but beat down with delays in FDA approval. Not saying it goes there, but $2-$3 could be pretty easy with partnership announcement.
Move today was all in last half hour incidentally.
I alerted AMDA here at about .80 2 weeks ago
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=124384765&txt2find=AMDA
Won't post here anymore as I'm not "pumping to sell" and don't want to give that impression. I'm in this one cheap and believe it's going to be a big runner in next 6-12 months.
$AMDA I just started following it a few weeks ago. It has one of the worst 52 week charts I've ever seen due to repeated delays in FDA approval.
I think it goes (much) higher due to past statements of management that with (this) FDA approval they would announce partnerships for commercialization.
They also have a big deal in China that is waiting on approval from their FDA equivalent. That might happen faster due to FDA approval now.
http://finance.yahoo.com/news/amedica-signs-exclusive-chinese-silicon-131500135.html
Another new and exciting revenue source could be 3D printing of Silicon Nitride joints. AMDA is first to 3D print Silicon Nitride- and it has many advantages over other composites.
More at: https://3dprintingindustry.com/news/silicon-nitride-biomaterial-gets-3d-print-treatment-for-the-first-time-ever-75242/
Also, company has about $19-$20M in annual revenues before this product launch, and a P/S ratio of < 1 with market cap only $25M here. Lots of room to run higher there
Anyway- I think there could be a run in this one to $2 or even $3 by end of week with + news, especially if they have a partnership in the wings to announce following FDA approval as has been suggested by management.
$AMDA - float < 22M, could trade that easily tomorrow with pr.
Especially if they have commercialization partnerships to announce as they've indicated they'll have (should FDA approval come) previously.
Going to be an exciting week.
I'm guessing they'll pr it tomorrow.
Agreed- heck- what's the rush for a pr.
It could come out next week as far as I'm concerned- more time to add for those with higher cost averages.
Also- with FDA approval, will China deal will likely move forward.
Several partnerships probably to be announced with approval behind them now.
For those who've been here for months/years, the wait is finally over.
yep
Because my dca is about .77 now, so I'm very happy.
Holding for the 3D printing of SiN3 to be realized.
$AMMDA - FDA has + info on site...no pr yet from company on approval
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K161405
$3 stock by Friday
"The massive recovery rally is now set to begin on Monday."
OMFG that's funny.
Sonny Bal Removal Petition
http://www.ipetitions.com/petition/balsgottogo
Market at all-time highs- $AMDA at all-time lows.
Congratulations to the management at AMDA, where the wholesale destruction of shareholder value continues.
Sonny Bal Removal Petition
http://www.ipetitions.com/petition/balsgottogo
Ain't that the truth
re: "In the end, you'll always have some on ihub promoting and excusing endlessly"
And tax loss selling season starts in a few weeks. Without FDA announcement, look for .50 and under.
With FDA announcement, it will see a quick pop tor a 10-20% gain on massive volume, followed by a slow leak of sellers on declining volume who have been waiting to get out and expected to (somehow) break even.
*Mark this post
we'll see.
Market determines valuation, not ihub posters.
Sorry, that's the simple truth.
Um...anyone that's been here for more than a year...
re: Who needs the stock to recover to $9.60?
I'm a realist.
The stock will never recover to prior highs of this year.
$1.00-$1.25 maybe with FDA approval- and they better get it soon or it's going to the pink sheets.
re: "looks like the cavalry is on the way.."
I'm not seeing it....
A gain of > 1,000% is what it would take to get back to 52 week highs.
That's pretty sad that some are that much in the red here!
And the stock is not "consolidating" it's continuing to be sold off.
And the fact is there's a very small short position here- it's just plain selling.
Even with FDA approval, a gain of 50% would only get shares back to $.975 (!)
So anyone from over $1 dca here (which is 95% of this board I'd estimate) will never see green in the stock unfortunately.
lol
this is NOT a "quiet consolidation"
It's a continuation of the selling my friend.
With that, I agree completely! :)
Thanks- I'll ask about autologous stem cells also.
I added more here at .67.
Bottom in I'd say. P/S well below 1 and near term financing in place. As a biotech stock, I see no reason for this to go any lower.
Risk from shorting (which has its place many times), appears too great.
$XXII Breaking Out
http://microcapresearch.com/xxii-breaking-out/
MUCH more to come
Added at .63 and have dca of .79 now. Will add tomorrow for a full tank of this one.
Selling should be done by tomorrow- we'll see.
Hope to get in touch with management re: their 3D printing aspirations in the next week or so.
$GSPH chosen as $GOOG partner with New Federal Law that REQUIRES 3D Underground Mapping Driving Demand.
HUGE!!!
http://microcapresearch.com/geospatial-corporation/
Might all the diversions of Salt Lake City
When I was there last there was an undercurrent of pent-up tension that I won't go into- but there is a very interesting and active underground in Salt Lake City.
Back to AMDA
Disappointed that they've not met the 60 day FDA timeline they has out there, but believe they are close after listening to the conf call over the weekend.
As for share price- it will do what it will do- manipulation or not. The short position is quite small here actually, but it certainly trades as though it's being shorted quite a bit.
My guess is today or tomorrow will be a good place to add more. Those who were disappointed by the results/lack of FDA announcement will be out by tomorrow.
Your definition of accumulation must differ from mine.
re: "Price action shows signs of accumulation."
$AMDA FDA decision this week on clearance of Composite Interbody Spinal Device
(60 days from June 13 = this week.)
Amedica Corporation ( NASDAQ : AMDA ), a company that develops and commercializes silicon nitride ceramics, announced that it has submitted its responses to the Food and Drug Administration (FDA) in relation to the CASCADE clinical trial.
The CASCADE study compared the 24-month outcomes from single-level cervical fusion between Amedica's porous silicon nitride versus bone autograft. Data showed that porous silicon nitride achieved clinical and radiographic outcomes that were comparable to bone autograft.
"Porous silicon nitride is a synthetic platform that can achieve spinal fusion without added bone graft, based on the results of our clinical trial," said Dr. Sonny Bal, chairman and CEO of Amedica Corporation. "These outcomes are consistent with our understanding of the surface chemistry and nano-topography of silicon nitride. We believe the composite porous silicon nitride fusion device used in the CASCADE trial, if approved by the FDA, will improve patient health. We are confident that we have addressed the questions raised by the FDA."
The Company anticipates a final determination from the FDA within the next 60 days. If approved, the Company would commence manufacturing, marketing and sales of the product in the United States and its possessions subject to FDA jurisdiction.
http://finance.yahoo.com/news/amedica-submits-response-fda-clearance-131500600.html
Interesting company was recently the 1st to 3D print Silicon Nitride for Medical applications.
http://3dprintingindustry.com/news/silicon-nitride-biomaterial-gets-3d-print-treatment-for-the-first-time-ever-75242/
It depends on what is being 3D printed as to whether it will reduce manufacturing time and cost.
Present printing speeds are too slow for mass production of identical items.
For intricate parts that are small production runs, or custom one of a kind parts (or bones in this case), it is ideal.
Agreed.
If they're truly going to enter 3D printing of composite replacement joints, then this is a different animal going forward. So an update on where they are would be useful.
That's why I'm trying to get a Q&A scheduled when they're ready- what they're looking to enter is a specialized niche with so far just a few players and huge market growth ahead.
Both DDD and SSYS reported better than expected Q2 results this week- and both cite growth in medical applications as a major driver.
From Markets and Markets:
The market is poised to grow at a CAGR of 25.3% from 2015 to 2020, to reach USD 2.13 Billion by 2020.
On the basis of components, the global 3D printing medical devices market is segmented into 3D printing equipment, materials, and services & software. The 3D printing equipment market is further segmented into 3D printers and 3D bioprinters; while, the materials segment is further classified into plastics (thermoplastics and photopolymers), metal and metal alloy powders, biomaterials, and others (ceramic, nylon, paper, and wax).
On the basis of medical products, the global 3D printing medical devices market is divided into surgical guides (dental guides, craniomaxillofacial (CMF) guides, and orthopedic implants), surgical instruments (retractors, scalpels, and surgical fasteners), prosthetics and implants (standard implants and custom implants), and tissue engineering products (bone & cartilage scaffolds and ligament & tendon scaffolds).
A number of factors such as continuous technological advancements in 3D printing, rising public and private investments to develop new 3D printing technologies and applications, and growing acceptance of 3D-printed organs and implants are fueling the demand of this market. In addition, growing demand of organ transplantation, strong mergers and acquisitions to enhance market share, and expiry of key patents are offering new growth opportunities for existing market players as well as new entrants in the global 3D printing medical devices market. On the other hand, the stringent regulatory process for the approval of 3D-printed medical products and high cost of 3D-printed organs are restricting the number of end users in the global 3D printing medical devices market.
As of 2015, North America holds the largest share of the global 3D printing medical devices market, followed by Europe. However, the Asia-Pacific market is expected to grow at the highest CAGR from 2015 to 2020. A number of factors, including increased government funding to enhance 3D printing applications in the healthcare industry, establishment of research and training centers, and rising awareness of 3D printing through conferences and events are propelling the growth of the 3D printing medical devices market in the Asia-Pacific region. However, dearth of skilled professionals and high cost of 3D printing systems restricts its demand in the developing Asian countries.
Stratasys Ltd. (Israel & U.S.), 3D Systems Corporation (U.S.), EnvisionTEC GmbH (Germany), EOS GmbH Electro Optical Systems (Germany), Renishaw plc (U.K.), Materialise NV (Belgium), 3T RPD, Ltd. (U.K.), Arcam AB (Sweden), Concept Laser GmbH (Germany), and Prodways (France) are the key players operating in the global 3D printing medical devices market.
http://www.marketsandmarkets.com/PressReleases/3d-printing-medical-devices.asp
No, "every buy" does not put a cap on the stock.
Only buys intended for a 5-10% pop.
And if that's what is going on here- then that's what you'll see on FDA approval.
Time will tell. Lets see what happens if FDA approves. I'm guessing $1 will not be crossed, but certainly hope it is as a shareholder- or the delisting countdown will begin, followed by another reverse split. The cycle could continue...
Don't mine me- was thinking out loud I guess.
But to answer your question, if someone is accumulating purely for the purpose of selling on a 5-10% pop on FDA news- then YES...that could put a lid on the stock.
Not circular logic at all. It's supply and demand.
If that's true, then the same person(s) "scooping it up big time" will be sellers if FDA decision is positive, and stock may not even respond positively to ruling. $1 may be history.
I bought this as a pure contrarian play. It has about the ugliest 2 year chart I've ever see...and I like the 3D printing they're looking at developing.
If AMDA were to gain recognition over time as a 3D printing-related stock, it would triple/quadruple on that alone. Those stocks don't need to make money- and none of them trade for a P/S anywhere near where AMDA trades. Look at ONVO- market cap 428 million on 1.2m in annual sales(!)
And bioprinting is only slightly cooler than 3D printing unique, perfectly shaped, custom, composite joints that are stronger than the original. It's a fairly new frontier in orthopedics.
I emailed and called Mike Houston and asked for a Q&A with CEO re: their 3D printing plans which I'd publish on several industry sites (Engineering.com, my site, 3DPrintingIndustry.com, etc.)
Haven't heard back yet- but suspect they're occupied with 10-Q coming and FDA, so I'll be patient.
Any thoughts as to volume/price surge on 7/28?
All the action took place in last 30 minutes then stopped.
Short covering is my guess.
Now market in big rally mode to new highs on strong employment report, and ADMA trading like FDA is a no-go and earnings will suck...
3D Printing Stocks Rally on 3D Systems’ Q2 Results
https://3dprintingstocks.com/3d-printing-stocks-rally/
Incidentally, a P/S ratio of 0.7 is by far the lowest of ANY stock that has ANY connection to 3D printing.